Vertex Pharmaceuticals announced plans to acquire Crinetics Pharmaceuticals in a $10 billion transaction, lifting Vertex’s commercial endocrinology footprint and adding late-stage pipeline assets. Vertex will pay $85 per share in cash, with both companies’ boards approving the deal; closing is expected in the third quarter of 2026. Crinetics’ lead commercial product is Palsonify, which treats acromegaly, a rare endocrine disorder. Vertex also expects to bring in additional Crinetics programs, including a late-stage therapy for congenital adrenal hyperplasia. The scale of the transaction underscores how large biopharma is prioritizing revenue-generating assets alongside pipeline expansion. For Crinetics, the headline impact was immediate—shares rose sharply in after-hours trading following the announcement. Overall, the deal reflects continued consolidation in biopharma as companies seek to pair established commercial drugs with clinical-development optionality in areas where blockbuster opportunities exist but differentiation can be harder to achieve organically.